Version history

{
  "session_id": "sess-hyp-87b85c3b19fe",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "llm",
  "action": "synthesize",
  "content": "\n\n# Scientific Synthesis: EC-II SST Interneuron tACS Hypothesis\n\n## Synthesis of Prior Debate Rounds\n\n### Core Mechanistic Claims\nThe hypothesis proposes a tripartite mechanism:\n1. **SST interneuron dysfunction** → disinhibition of EC-II stellate cells\n2. **Disinhibition** → aberrant gamma oscillations (30-80 Hz) and tau propagation along perforant path\n3. **Closed-loop tACS** → restore inhibitory tone and excitatory-inhibitory balance\n\n### Cross-Round Convergence Points\n\n| Dimension | Theorist | Skeptic | Domain Expert | Consensus |\n|-----------|----------|---------|---------------|-----------|\n| Anatomical substrate validity | Strong | Strong | Strong | ✓ |\n| Mechanistic coherence | Moderate-High | Moderate | Moderate | ✓ |\n| tACS cell-type specificity | Not addressed | Critical concern | Critical concern | ✗ |\n| Causality evidence | Weak | Weak | Weak | ✗ |\n| Translational feasibility | Challenged | Challenged | Highly challenged | ✗ |\n\n---\n\n## Dimension Scores\n\n| Dimension | Score | Rationale |\n|-----------|-------|-----------|\n| **Mechanistic_plausibility** | 0.68 | SST+ interneuron inhibition of stellate cells is established; linking to tau propagation is speculative. Disinhibition → tau propagation lacks direct mechanistic pathway. |\n| **Evidence_strength** | 0.52 | rTg4510/PS19 mouse data supporting SST dysfunction precedent is valid, but causality chain remains inferential. Human evidence absent. |\n| **Novelty** | 0.91 | Closed-loop gamma tACS targeting EC-II specifically is genuinely innovative; integrates multiple cutting-edge approaches. |\n| **Feasibility** | 0.35 | **Primary weakness**: tACS cannot achieve EC-II SST-specific targeting. Depth penetration and spatial specificity remain unresolved. |\n| **Therapeutic_potential** | 0.58 | If specificity barriers could be overcome, the therapeutic window could be substantial given early disease targeting. |\n\n---\n\n## Strengths and Weaknesses\n\n### Strongest Aspects\n1. **Target legitimacy**: SST+ interneurons in EC-II represent a valid, anatomically grounded therapeutic target\n2. **Mechanistic integration**: Unifies gamma dysfunction, tau propagation, and circuit-level pathophysiology—addressing a genuine gap in AD therapeutics\n3. **Preclinical grounding**: Tau transgenic mouse models provide plausible disease-relevance\n4. **Dynamic intervention**: Closed-loop approach acknowledges the temporal dynamics of pathology\n\n### Weakest Aspects\n1. **tACS specificity failure**: Cannot selectively recruit SST+ interneurons; will recruit heterogeneous neuronal populations\n2. **Causality gap**: SST dysfunction correlates with tau pathology but mechanistic link (disinhibition → tau propagation) is",
  "tokens_used": "671",
  "persona_id": "persona-synthesizer"
}